New research shows promising results for preventing chemotherapy-induced neuropathy, discussing treatment options, including photobiomodulation therapy. The podcast explores the specific laser therapy used in the study and highlights the positive outcomes seen in breast cancer patients. The use of robotic and class four lasers for treating neuropathy is also discussed, along with a free webinar on starting treatment.
Chemotherapy-induced peripheral neuropathy (CIPN) is a common problem that affects many patients undergoing chemotherapy. A study published in Supportive Care and Cancer investigated the use of photobiomodulation therapy (laser therapy) for the prevention of CIPN. The study found that treating patients with laser therapy twice a week during their chemotherapy regime resulted in a significant improvement in neuropathy symptoms and functional capacity compared to the control group. The treatment group experienced fewer symptoms such as numbness and discomfort in the hands and feet, and had better endurance as measured by the six-minute walk test. Though more research is needed, these findings highlight the potential benefits of early intervention with laser therapy to prevent CIPN in breast cancer patients.
The Promise of Photobiomodulation Therapy
Photobiomodulation therapy, also known as laser therapy, has shown promising results in the prevention of chemotherapy-induced peripheral neuropathy (CIPN). By utilizing safe and non-invasive light, this therapy stimulates cell viability, accelerates axonal growth, and suppresses neural apoptosis. The study discussed in the podcast demonstrated that patients receiving laser therapy alongside chemotherapy experienced fewer symptoms of CIPN and better functional capacity compared to the control group. This finding suggests that incorporating photobiomodulation therapy early in the treatment process may help patients stay on their chemotherapy regimen and minimize the impact of neuropathy.
The Power of Early Intervention
The podcast highlights the importance of early intervention in managing chemotherapy-induced peripheral neuropathy (CIPN). The study discussed investigated the use of photobiomodulation therapy in breast cancer patients undergoing chemotherapy. By initiating laser therapy immediately at the start of chemotherapy treatment, it was observed that patients experienced a reduction in symptoms and better quality of life compared to the control group. This early intervention approach may have significant benefits, as it can help patients stay on their chemotherapy regimen without interruption, leading to improved outcomes in cancer treatment. Further research is needed to explore the full potential of early intervention with laser therapy for preventing CIPN.
New research on chemo-induced neuropathy PREVENTION shows promising results for patients undergoing cancer treatment. Learn what the researchers found and how it can impact your practice!
